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Abstract 
Background: This study aimed to evaluate the markers of insulin resistance and adipokine status in patients with vis-
ceral obesity during hospitalization following myocardial infarction (MI) and assess the disturbances of carbohydrate 
metabolism present 1 year after MI onset.
Methods: 94 male patients with MI were recruited. The exclusion criteria were as follows: age less than 50 or greater 
than 80 years, the presence of type 2 diabetes mellitus (T2DM), and a prior history of pronounced renal failure.Obesity 
types were defined according to body mass index (BMI), waist circumference (WC) and visceral adipose tissue (VAT) 
area. Glucose, insulin, adiponectin, leptin, and insulin resistance (IR) index were measured on days 1 and 12 after the 
onset of MI. New-onset type 2 diabetes was assessed 1 year after MI onset.
Results: According to computed tomography assessments of all study patients, 69 % of patients with MI suffered 
from visceral obesity. The VAT area was more closely associated with the risk of developing type 2 diabetes compared 
with the obesity parameters, BMI and WC. Patients with a VAT area greater than 130 cm2 had a 3.6-fold higher risk 
of developing type 2 diabetes. The presence of IR and hyperleptinemia increased the risk of developing diabetes in 
the post-MI period 3.5 and 3.7 times, respectively, in patients with visceral obesity compared with patients without 
visceral obesity.
Conclusion: Visceral obesity is associated with IR, a 5.7-fold increase in leptin levels and a high risk of developing 
type 2 diabetes 1 year after MI onset.
Keywords: Carbohydrate metabolism disorders, Myocardial infarction, Inflammation percutaneous coronary 
intervention, Adipose tissue, Diabetes, Insulin resistance, Adipokines, Myocardial infarction
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Background
Currently, obesity is recognized as one of the primary 
elements in the pathogenesis of cardiovascular disease 
(CVD) and type 2 diabetes mellitus (T2DM) [1]. Vis-
ceral fat is reported to be far more dangerous than any 
other form of obesity [2]. Visceral adipose tissue (VAT) 
is known to be an independent risk factor of myocardial 
infarction (MI) in elderly patients (55/60–74  years) or 
patients at an advanced age (75–90) [3]. Recently, a rela-
tionship between excessive accumulation of adipose tis-
sue in the visceral depot and progression of heart failure 
in patients after MI was reported [4].
Body mass index (BMI) is a traditional measure of 
obesity. Although BMI values may be within the nor-
mal range, patients may still have excessive abdominal 
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circumference (WC) is considered to be an indicator of 
abdominal obesity, but it has not been found to be a suf-
ficiently accurate indicator of the risk of developing CVD 
and T2DM [5]. Computed tomography (CT), however, 
can be used in clinical practice to measure visceral fat [6].
VAT is not only a storage organ for excess energy; 
rather, it is an active endocrine organ responsible for 
the synthesis and secretion of hormone-like substances 
known as adipokines [7]. Adipokines have diverse roles 
in regulating different metabolic processes in the body, 
ranging from food intake to nutrient recycling at a 
molecular level [4]. Reportedly, an excess of VAT is asso-
ciated with increased release of adipokines, contribut-
ing to the development of insulin resistance (IR) [3]. 
It has been hypothesized that during the occurrence of 
MI, catecholamine stress can worsen IR and may lead to 
the development of diabetes. The aim of this study was 
to investigate the markers of IR and adipokine status in 
patients with visceral obesity during hospitalization fol-
lowing MI and to assess the disturbances of carbohydrate 
metabolism 1 year after MI.
Methods
Study population
Ninety four male patients who were admitted to our 
hospital for MI between January 2008 and December 
2010 were recruited, and the diagnosis of MI was veri-
fied using the All-Russian Scientific Society of Cardiol-
ogy (2007) and European Society of Cardiology (ESC), 
the American College of Cardiology Foundation (ACCF), 
the American Heart Association (AHA), and the World 
Heart Federation (WHF) [8] diagnostic criteria for the 
diagnosis of MI: i.e., the presence of typical pain lasting 
longer than 15 min, electrocardiographic (ECG) changes 
(ST segment elevation in at least two consecutive leads) 
and laboratory findings (elevated creatine phosphoki-
nase [CK], creatine phosphokinase-MB [CK-MB], and 
troponin T levels). The exclusion criteria were as follows: 
age less than 50 or greater than 80 years, the presence of 
T2DM, and a prior history of pronounced renal failure 
(glomerular filtration rate <30 mL/min). We recruited 33 
participants without CVD or T2DM as controls. These 
participants were comparable to the enrolled patients in 
terms of age and sex.
The examination scheme and clinical assessment of 
patients included the collection of patient complaints and 
past medical history; physical examination; ECG record-
ing; measurement of body weight (kg), height (cm), WC 
and hip circumference (HC) (cm); and calculation of 
BMI (kg/cm2) and waist-to-hip ratio. All the patients 
underwent multi-slice computed tomography on a com-
puted tomography (Lightspeed VCT 64, General Electric, 
Fairfield, CT, USA) for the measurement of abdominal 
adipose tissue. The CT scans were performed at the L4 
and L5 level, with the patients lying flat on their backs, 
with their hands raised, and holding their breath. A recon-
struction slice thickness of 1 mm was used to reduce the 
effect of summation of adjacent tissue densities. VAT and 
subcutaneous adipose tissue (SAT) areas were measured, 
as well as the ratio of VAT to SAT. Two diagnostic criteria 
were used to confirm visceral obesity: a VAT area above 
130 cm2 and a ratio of VAT to SAT above 0.4 [8]. Patients 
were categorized into two groups according to the CT 
findings: Group 1 (n = 64) included patients with visceral 
obesity (VAT area ≥130  cm2 and VAT/SAT ratio ≥0.4), 
and Group 2 (n = 30) included patients without visceral 
obesity (VAT area <130 cm2 and VAT/SAT ratio <0.4).
All the patients underwent primary percutaneous coro-
nary intervention of the infarct-related artery as reper-
fusion therapy. During the hospitalization period (mean 
duration of 12 days), all the patients received β-blockers, 
angiotensin converting enzyme inhibitors, calcium chan-
nel blockers, diuretics, nitrates, aspirin, heparin, clopi-
dogrel and statins.
The homeostasis model assessment method for 
evaluating IR (HOMA-IR) was used to assess IR. The 
HOMA-IR was calculated using the following formula: 
HOMA-IR =  [fasting insulin (mkME/ml) ×  fasting glu-
cose (mmol/l)]/22.5. A value of HOMA-IR above 2.77 
implied the presence of abnormally high IR.
Glucose tolerance test
All the patients (on day 12) underwent a 75-g oral glucose 
tolerance test (OGTT) according to specialized medical 
care standards to verify the diagnosis of T2DM. Blood 
glucose was measured after an overnight fast of 8–14 h 
and 2 h after a standard glucose load of 75 g (dissolved in 
300 ml of water). Three days before the test, the patients 
were on an arbitrary (unbounded) diet. They maintained 
adequate physical activity according to the individual 
patient’s ability. The last evening meal contained 30–50 g 
of carbohydrates. Additionally, smoking was prohibited 
during the OGTT.
Patients with a fasting blood glucose level above 
7.8  mmol/l underwent postprandial glycemia measure-
ments 2  h after a meal containing 20–24  g of carbohy-
drates, 6–9 g of protein and 8–11 g of fat. The diagnostic 
criteria (WHO, 1999–2006) [6] for T2DM were fasting 
plasma the glucose level above 7.0  mmol/l or a glucose 
level above 11.1  mmol/l 2  h after an OGTT. A HbA1c 
level above 6.5 % was also used as a diagnostic criterion 
for T2DM.
Blood sampling and biochemical assays
Venous blood was collected from all patients. Serum was 
separated from venous blood by centrifugation at 3000×g 
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for 20 min and stored at −70 °C. At days 1 and 12 from 
the MI onset, serum glucose insulin and C-peptide levels. 
Glucose levels were measured using a standard Thermo 
Fisher Scientific test system (Thermo Fisher Scientific 
Oy, Vantaa, Finland) in a Konelab 30i biochemistry ana-
lyzer (Thermo Fisher Scientific Oy). The intra-assay coef-
ficients of variation (CV) for insulin Diagnostic Systems 
Laboratories (Webster, TX, USA) and C-peptide ELISA 
(Waterloo, Australia) were 3.8 and 4.2  %, respectively, 
and the inter-assay CV were 6.9 and 7.9 %, respectively. 
Adipokine, leptin and adiponectin levels were meas-
ured with the BioVendor R and D Product (Brno, Czech 
Republic), and the intra-assay CV were 5.9 and 6.8  %, 
respectively.
Statistical analysis
Statistical analysis was performed using Statistica 6.1 
(InstallShield Software Corp., Chicago, IL, USA) and 
SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA). 
The Kolmogorov–Smirnov test was used to assess the dis-
tribution of two data sets. The results were presented as 
the median (Me) and the 25 and 75 % quartiles (Q1;Q3). 
The statistical analyses were performed using the non-
parametric Mann–Whitney test and the Wilcoxon test 
for skewed distributions. The exact Fisher’s test was used 
to analyze the difference in the frequencies in two inde-
pendent groups with two-sided confidence intervals. 
Stepwise logistic regression and a receiver operating 
characteristic (ROC) curve with the area under the curve 
(AUC) measurements were used to determine the most 
informative visceral obesity parameters, with hazard 
ratios (HR) and confidence intervals (95  %). Differences 
were considered statistically significant at p < 0.05.
Results
Clinical and demographic data are shown in Table  1. 
The mean age of the patients was 58.7 (52.2–69.9) years. 
The mean age of the control group was 58.42 (52.2–61.1) 
years. The anthropometric measurements were BMI of 
24.3 (21.8–24.9) and WC of 92  cm (79–93) and a VAT/
SAT ratio below 1.0, which did not exceed the range for 
abdominal fat at this age. The CT findings demonstrated 
that none of the control subjects suffered from visceral 
obesity (VAT area of 110.0 [104.0–128.0] cm2 and VAT/
SAT ratio of 0.35 [0.2–0.39]).The groups were compa-
rable in age and presence of risk factors for coronary 
artery disease (CAD) such as hypertension (AH), smok-
ing, signs and symptoms of angina pectoris prior to MI, 
congestive heart failure and acute cerebrovascular acci-
dents (p  >  0.05). However, patients with excessive VAT 
had more frequent family history of T2DM and CAD, as 
well as a history of MI compared with patients without 
excessive VAT (p < 0.05). A similar prevalence of anterior 
Q-wave MI was found in both groups (p  >  0.05). There 
were no significant differences between groups in terms of 
complication rates during hospitalization for MI and left 
ventricle (LV) ejection fraction (p > 0.05). Patients in both 
groups suffered from multivessel CAD. However, severe 
atherosclerotic lesions of coronary arteries were found in 
patients with excessive VAT (e.g., 3-vessel disease).
The anthropometric measurements showed that 69  % 
of MI patients suffered from visceral obesity. Patients 
with normal weight and those with overweight were 
equally distributed among patients with excessive VAT 
(Table  2). The BMI values were lower in patients with 
visceral obesity compared with patients without it. 
Patients in Group 2, without visceral obesity, tended to 
have higher BMI and be overweight. Moreover, patients 
with grade 3 obesity were more likely to be found in this 
group. Abdominal obesity (WC > 94 cm) was more likely 
to be found in patients without visceral obesity and may 
be associated with increased SAT area, rather than VAT.
Taking into consideration the close pathogenetic rela-
tionship between obesity and IR, the IR markers (insulin 
levels, C-peptide levels and HOMA-IR) and basal and 
postprandial glucose levels were measured on days 1 and 
12 from MI onset. Levels of carbohydrate metabolism 
markers are shown in Table 3. In both groups of patients 
as compared with the control group, elevated glucose 
levels were found on day 1 of the MI treatment (Table 3). 
Further, patients with visceral obesity had a constantly 
elevated glucose level during the entire follow-up period. 
However, in patients without visceral obesity, glucose 
levels decreased on day 12 (p  >  0.05) to similar values 
compared with the control subjects.
High glucose levels in patients with visceral obesity 
were accompanied by an increase in HOMA-IR values, 
insulin and C-peptide levels compared with patients 
without visceral obesity. On day 1 of the MI treatment, 
basal insulin levels, C-peptide levels and HOMA-IR 
values increased 1.42-, 1.28- and 1.6-fold, respectively, 
in comparison with patients without visceral obesity 
(Tables 3, 4). There was a decrease in insulin and C-pep-
tide levels in both groups on day 12. Patients with visceral 
obesity presented 1.34 times higher insulin levels com-
pared with patients without visceral fat. HOMA-IR val-
ues did not change significantly in patients with excessive 
VAT on day 12, while in subjects without visceral obesity, 
these values decreased and reached similar values com-
pared with the control subjects.
During the MI treatment, an increase in basal and post-
prandial glucose levels as well as in insulin and C-peptide 
levels was found. However, more pronounced disorders 
were found in patients with visceral Postprandial glu-
cose, insulin and C-peptide levels were 1.31-, 2.0- and 
1.45-fold higher, respectively, in Group 1 than in Group 
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Table 1 Baseline clinical characteristics of patients
p value for differences between groups (P < 0.05)
HIS ischemic heart disease, T2DM type 2 diabetes mellitus





Age, years 58 (54.69) 59 (50.67) 0.92
Arterial hypertension, n (%) 64 (100.0) 25 (83.3) 0.05
Current smoking, n (%) 36 (56.6) 16 (53.3) 0.46
Family history of IHD, n(%) 42 (65.6) 10 (30.0) 0.04
Family history of T2DM, n (%) 14 (21.8) 3 (10.0) 0.04
Angina prior to myocardial infarction, n (%) 34 (53.1) 20 (66.6) 0.65
Previous myocardial infarction, n (%) 12 (18.8) 5 (16.6) 0.04
History of heart failure, n(%) 6 (9.3) 3 (10.0) 0.75
History of cerebrovascular accident/transient  
ischemic attack, n (%)
0 1 (3.3) 1.0
Myocardial infarction
 Q-wave myocardial infarction 51 (79.6) 24 (80.0) 0.59
 Non-Q-wave myocardial infarction 13 (20.4) 6 (20.0) 0.67
Localization of myocardial infarction
 Posterior 42 (65.6) 16 (53.3) 0.62
 Posterior with extension to the right ventricle 7 (10.9) 4 (13.3) 0.68
 Anterior 12 (18.8) 8 (26.6) 0.54
 Inferio- posterio-lateral 3(4.7) 2 (6.6) 0.73
Acute heart failure (Killip classification)
 I 44 (68.7) 20 (66.6) 0.67
 II 13 (20.3) 7 (23.3) 0.55
 III 6 (9.3) 3 (10.0) 0.69
 IV 1 (6.4) 0 1.00
 Rhythm disturbance, n (%) 17 (26.6) 8 (26.6) 0.85
Early post-infarction angina, n (%) 12 (18.7) 6 (20.0) 0.74
Recurrent myocardial infarction, n (%) 3 (4.6) 1 (3.3) 0.89
Creatine phosphokinase, U/l 340.2 (213.1,7;738.4) 253 (115.7; 534.1) 0.02
Max creatine phosphokinase-MB, U/l 83 (37;178) 67 (36; 144) 0.04
Troponin T, ng/ml 1.1 (0.88:3.1) 0.71 (0.17:1.2) 0.01
Left ventricular ejection fraction,  % 51 (43;58) 54 (43; 57) 0.627
Number of diseased coronary arteries
 Stenosis of a vessels 10 (15.6) 6 (20) 0.79
 Stenosis of two vessels 6 (9.4) 10 (33.3) 0.03
 Stenosis of three or more vessels 48 (75.0) 14 (46.6) 0.04
Treatment strategy/group of drugs
 Stenting of the infarct-related artery 64 (100) 30 (100) 0.79
 Systemic thrombolytic therapy 5 (7.8) 3 (10.0) 0.76
 β-Blockers 63 (98.4) 30 (100) 0.82
 Angiotensin-converting enzyme 58 (90.6) 26 (86.7) 0.68
 Calcium channel blocker 53 (82.8) 24 (82.8) 0.98
 Diuretics 22 (34.3) 11 (36.6) 0.83
 Nitrates 9 (14.0) 4 (13.3) 0.77
 Aspirin 64 (100) 29 (96.6) 0.92
 Heparin 64 (100) 30 (100) 0.98
 Clopidogrel 57 (89.0) 27 (90.0) 0.83
 Statins 64 (100.0) 30 (100.0) 0.98
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2. Postprandial glucose and insulin were 1.6- and 2.8-fold 
higher than in the control group (p < 0.05), respectively. 
Notably, there were no significant differences in C-pep-
tide levels between both groups compared with the con-
trol subjects.
Adipokines have a primary role in regulating carbo-
hydrate metabolism. Although all MI patients presented 
an imbalance in the adipokine status indicators, these 
changes were far more pronounced in patients with vis-
ceral obesity (Table  4). On day 1 from the onset of MI, 
patients in Group 1 showed a 2.0-fold increase in leptin 
levels compared with patients without visceral obesity 
and a 5.7-fold increase compared with the control group. 
On day 12, patients with excessive VAT reported a 1.4-
fold decrease in leptin levels.
Importantly, adiponectin levels decreased by 1.7-fold 
in patients with visceral obesity on day 1 from the onset 
of MI compared with control subjects, and decreased by 
1.3-fold compared with patients without visceral obesity. 
On day 12 of the MI treatment, adiponectin remained at 
low levels in Group 1, whereas in Group 2, the adiponec-
tin levels increased nearly to the baseline values.
Carbohydrate disorders and adipokine imbalance in 
patients with visceral obesity were associated with the 
Table 2 Anthropometric indicators of obesity in patients with myocardial infarction
Data in the table are presented as median (Me) and 25 and 75 % quartiles (Q1;Q3) or n (%)
p value for differences between groups (p < 0.05)
VAT visceral adipose tissue, BMI body mass index, SAT subcutaneous adipose tissue, HC hip circumference, WC waist circumference
Variable Patients with visceral  
obesity, n = 64
Patients without visceral  
obesity, n = 30
p value
BMI, kg/m2 26.7 (19.0;42.0) 29.4 (25.1;39.2) 0.02
Normal weight, n (%) 24 (37.5) 6 (20) 0.02
Overweight, n (%) 20 (31.5) 14 (46.6) 0.2
I obesity, n (%) 15 (23.4) 2 (6.7) 0.01
II obesity, n (%) 3 (4.7) 2 (6.7) 0.23
III obesity, n (%) 2 (3.1) 6 (20) 0.03
WC, cm 103.8 (84.0;124.0) 96.8 (78.0;123.0) 0.04
HC, cm 97.7 (90.0;120.0) 101.2 (84.0;140.0) 0.04
WC/HC 1.0 (0.9;1,2) 1.0 (0.7;1.1) 0.23
Area VAT, cm2 162.2 (130.3;196.4) 119.0 (102.1;129.2) 0.01
Area SAT, cm2 382.2 (236.4;435.0) 411.0 (334;470) 0.01
VAT/SAT 0.44 (0.38;0.62) 0.31 (0.18;0.55) 0.01
Table 3 Basal and postprandial carbohydrate metabolism and HOMA-IRmarkers in MI patients during hospitalization
Data in the table are presented as median (Me) and 25 % and 75 % quartiles (Q1;Q3). P value for differences between groups (p < 0.05)
MI myocardial infarction, HOMA-IR homeostasis model assessment method for the evaluation of IR
Variable Control group (n = 30) Patients with visceral obesity, n = 64 Patients without visceral obesity, n = 30
1st day 12th day 1st day 12th day
Basal level Postprandial 
level
Basal level Postprandial 
level
Basal level Postprandial 
level
1 2 3 4 5 6 7 8
Glucose,  
mmol/l
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onset of T2DM 1 year after MI. Diabetes was diagnosed 
in 11 patients in Group 1. Moreover, a further 11 patients 
in this group presented impaired glucose tolerance (IGT) 
and six patients had abnormal fasting glucose levels. 
Interestingly, there were no such findings in patients 
without visceral obesity.
Univariate logistic regression and ROC-analysis were 
performed to determine the prognostic value of anthro-
pometric measurements, biochemical results and bio-
markers for the risk assessment of developing diabetes 
1  year after MI (Table  5). The results showed that the 
VAT area had the highest predictive value among the 
anthropometric measurements. Patients with a VAT area 
equal to or above 130 cm2 were at a 3.6-fold higher risk 
of developing T2DM (AUC 0.91, p = 0.00). The BMI did 
not yield a high diagnostic accuracy. The HOMA-IR and 
the leptin levels measured on days 1 and 12 showed the 
highest diagnostic accuracy among the markers of carbo-
hydrate metabolism and adipokine status assessed.
Thus, patients with visceral obesity demonstrated unfa-
vorable prognosis following MI, i.e., the manifestation of 
T2DM in the long-term post-MI period. The biochemical 
basis of the pathological process is presented with basal 
and postprandial hyperglycemia, hyperinsulinemia and 
IR, as well as adipokine imbalance in acute MI. Moreover, 
it was more pronounced in patients with visceral obesity.
Discussion
Obesity is a commonly recognized risk factor of T2DM 
[1]. However, there are no informative indicators to 
assess the risk of developing T2DM in MI patients who 
are overweight in clinical practice [9].
BMI and WC are routinely used to assess overweight. 
Further, it is well known that these parameters are 
Table 4 Adipokine status indicators in patients with myocardial infarction with or without visceral obesity during hospi-
talization
Data in the table are presented as median (Me) and 25 and 75 % quartiles (Q1;Q3)
p value for differences between groups (p < 0.05)
Variable Control (n = 30) Patients with visceral obesity,  
n = 64
Patients without visceral obesity, 
n = 30
1st day 12th day 1st day 12th day
1 2 3 4 5























Table 5 Odds ratios for  diabetes based on  anthropomet-
ric and  biochemical parameters 1  year after  myocardial 
infarction
p value for differences between groups (P < 0.05)
BMI body mass index, VAT visceral adipose tissue, SAT subcutaneous adipose 
tissue, HC hip circumference, WC waist circumference, HOMA-IR homeostasis 
model assessment method for the evaluation of IR, OR odds ratio, CI confidence 
interval, AUC area under the curve
Variable OR 95 % CI AUC p value
BMI 1.3 1.0–1.1 0.55 0.07
WC 1.7 1.4–1.9 0.76 0.01
HC 1.6 1.4–1.8 0.72 0.01
WC/HC 1.9 1.8–2.3 0.84 0.01
VAT area, cm2 3.6 2.2–4.2 0.91 0.00
SAT area, cm2 1.1 0.9–1.2 0.55 0.09
VAT/SAT 1.6 1.4–1.8 0.72 0.01
Basal level glucose, 1st day, mmol/l 1.2 1.1–1.4 0.72 0.01
Basal level glucose, 12th day, mmol/l 1.3 1.1–1.5 0.74 0.03
Postprandial level glucose, 12th day, 
mmol/l
1.9 1.6–2.1 0.82 0.00
Basal level insulin, 1st day, mU/ml 1.2 1.1–1.4 0.72 0.02
Basal level insulin, 12th day, mU/ml 1.3 1.1–1.5 0.77 0.04
Postprandial level insulin,  
12th day, mU/ml
1.6 1.2–1.8 0.79 0.01
Basal level C-peptide, 1st day, ng/ml 1.2 1.2–1.6 0.72 0.03
Basal level C-peptide, 12th day, ng/ml 1.5 1.1–1.5 0.76 0.03
Postprandial level C-peptide, 12th day, 
ng/ml
1.7 1.5–1.9 0.80 0.01
HOMA-IR, 1st day 1.8 2.9–4.1 0.75 0.01
Index HOMA-IR, 12th day 3.5 2.8–3.9 0.93 0.01
Adiponectin, 1st day, mg/ml 0.7 0.6–0.8 0.74 0.01
Adiponectin, 12th day, mg/ml 0.6 0.5–0.8 0.76 0.02
Leptin, 1st day, ng/ml 3.7 2.9–4.0 0.96 0.01
Leptin, 12th day, mg/ml 3.1 2.8–3.6 0.90 0.01
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correlated with the risk of developing CAD and diabe-
tes. WC is strongly associated with the risk of developing 
new-onset diabetes, as it reflects fat accumulation in the 
abdominal area, which is considered to be particularly 
unfavorable for developing cardiometabolic complications. 
However, in the present study, BMI had low value in terms 
of predicting the development of T2DM, with high BMI 
representing a 1.3-fold increased risk of developing diabe-
tes. Interestingly, WC and waist-to-hip ratio were far more 
valuable indicators. Abnormalities in these parameters 
represented a 1.7- and 1.9-fold, respectively, increased risk 
of developing manifestations of diabetes. Nevertheless, we 
found that the most valuable indicator of obesity associ-
ated with the risk of developing T2DM was the VAT area 
in the abdominal compartment, meaning that the presence 
of excessive visceral fat represents a 3.6-fold increased risk 
of developing T2DM. VAT area also had higher sensitivity 
compared with the other markers of abdominal obesity.
Low informative values of BMI and WC may be 
explained by the fact that these parameters do not account 
for the ratio of muscle, bone, fat mass and the distribution 
of adipose tissue. As VAT indicates the visceral fat area in 
the abdominal compartment, it therefore, represents the 
highest risk factor for developing CVD and T2DM. In this 
study, more than half of the MI patients suffered from vis-
ceral obesity according to the CT scan findings. The BMI in 
patients with visceral obesity was significantly lower than in 
those patients without visceral obesity. Similar results were 
presented in 2008 by Oreopoulos et al. [10], who showed 
that BMI in patients with chronic heart failure correctly 
reflected the amount of adipose tissue in 41 % of examined 
patients. In their cohort of middle-aged (62–66 years) nor-
mal-weight, overweight and obese patients, BMI was a bet-
ter indicator of lean body mass than of adiposity [10].
Excessive accumulation of visceral fat is a well-known 
indicator of obesity-related cardiometabolic changes [5]. 
In our study, visceral obesity was associated with multi-
vessel CAD and severe damage of cardiomyocytes during 
MI, as evidenced by elevated CK-MB levels in patients 
with visceral obesity. Excessive VAT is associated with 
higher levels of metabolic activity of adipocytes compared 
with SAT. The synthesis of fat and biologically active hor-
mone-like substances is more intense in VAT adipocytes. 
In contrast to SAT adipocytes, visceral fat cells are less 
sensitive to the effects of insulin and are more susceptible 
to catecholamines, which stimulate lipolysis and are espe-
cially important during catecholamine stress, common in 
MI [11]. Intensive lipolysis in visceral adipocytes leads to 
excessive release of free fatty acids in the hepatic portal 
circulation, entering the liver and decreasing the sensitiv-
ity of insulin receptors on hepatocytes. These events lead 
to impaired hepatic insulin clearance and the develop-
ment of systemic hyperinsulinemia.
Hyperinsulinemia enhances IR by violating autoregu-
lation in muscle insulin receptors. Our study results 
showed a 1.5-fold increase in HOMA-IR, other IR 
markers (insulin and C-peptide) and glucose in patients 
with visceral obesity during the hospitalization period 
compared with the healthy volunteers and the MI 
patients without excessive VAT. The most informative 
parameters for assessing the risk of developing T2DM 
were HOMA-IR, postprandial hyperglycemia and 
hyperinsulinemia.
Adipokines have a pivotal role in the development and 
progression of IR and its various manifestations during 
MI. They have a variety of local, peripheral and central 
effects, affecting food intake, metabolic processes, and 
oxidative stress in the cardiovascular system [12]. The 
present results indicate that there is an adipokine imbal-
ance in patients suffering from visceral obesity. Such 
patients presented increased leptin levels and decreased 
serum adiponectin levels during MI hospitalization com-
pared with the groups of control subjects and patients 
without visceral obesity (p  <  0.05). High leptin levels 
were associated with a 3.0-fold increased risk of develop-
ing T2DM in the post-MI period. Adipokine imbalance 
was found in patients without visceral obesity on day 1 
of the MI treatment, which seemed to subsequently sta-
bilize throughout the hospitalization. Previously, patients 
with MI were known to have higher serum levels of 
leptin regardless of body weight when compared with 
healthy subjects [13, 14]. These results may be associ-
ated with the activation of alternative sources of leptin 
in MI. Cardiomyocytes are known to be able to express 
adipokines, which apparently may be involved in regulat-
ing metabolism during MI. According to the experimen-
tal data, both endothelin-1 and angiotensin II increased 
leptin levels in cardiomyocyte cultures [15]. We found a 
high concentration of leptin in acute MI, which suggests 
ischemia-induced leptin production by adipocytes and 
cardiomyocytes. Further, a highly active VAT contributes 
to the total amount of leptin, which seems to limit the 
area of necrosis and contribute to myocardial regenera-
tion in the acute and early recovery phases of MI.
However, elevated blood levels of leptin are known to 
be closely associated with the development of IR, which 
is not only a sign of T2DM, but also a metabolic risk fac-
tor of atherosclerosis and MI [12]. Wallander et  al. [16] 
suggested that high serum leptin levels are a predictor 
of both repeated cardiovascular events and the develop-
ment of impaired carbohydrate tolerance in patients with 
MI. One of the pathophysiological mechanisms of this 
phenomenon is the ability of leptin to modulate the cell 
signaling pathways involved in the insulin, carbohydrate, 
lipid and energy metabolisms, resulting in increased 
myocardial injury during ischemia [12].
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Adiponectin levels decrease during MI compared with 
leptin levels. The concentration of adiponectin within the 
normal range is usually determined by the size and the 
number of visceral adipocytes, which produce more adi-
ponectin than subcutaneous adipocytes. Paradoxically, 
obesity is characterized by decreased serum adiponec-
tin levels, which is apparently provoked by decreased 
adiponectin secretion [17]. Adiponectin production is 
reduced with obesity, which may be associated with the 
inhibition of adiponectin gene transcription by inflam-
matory angiogenic factors produced by hypertrophic 
adipocytes. According to our results, adiponectin levels 
in patients without visceral obesity tended to be within 
the normal range on day 12 of MI treatment, whereas 
in patients with visceral obesity, adiponectin levels 
remained significantly reduced. According to our results, 
the deficiency of adiponectin during the hospitalization 
period of MI increases the risk of diabetes by 30 %.
Conclusion
Visceral obesity in patients with MI is associated with 
more severe IR, leptin and adiponectin imbalance, and 
development of IGT and T2DM. Diagnostic criteria of 
obesity have different predictive values regarding the risk 
of developing T2DM. The VAT area was the indicator 
with the highest and BMI the indicator with the lowest 
diagnostic accuracy. Our results indicate there is a need 
for a differentiated approach in the diagnosis of obesity 
based on adipose tissue distribution. The CT assessment 
of the adipose tissue distribution seem to have higher 
predictive value than BMI. Further information regard-
ing predictors of a higher risk of cardiovascular events 
and T2DM will assist in initiating proper therapeutic and 
preventive interventions in patients with visceral obesity.
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